Calculate Adamax Dosage — Research Protocol Guidelines

Research published in the Journal of Peptide Science found that over 40% of peptide research failures stem from concentration miscalculations during the reconstitution phase. Not from contamination, degradation, or procedural errors. The problem isn't that researchers lack precision instruments. It's that they're calculating volume without accounting for the peptide's actual mass after lyophilization, which can vary by 8–12% from the labeled amount due to moisture content and excipient ratios.

When you're working with Adamax Peptide in a controlled research setting, the margin for error is essentially zero. A dosing miscalculation doesn't just skew your data. It can render an entire experimental protocol invalid. We've worked with research teams across metabolic and endocrine studies who discovered weeks into their protocols that their baseline concentration assumptions were off by 15–20%, forcing them to restart from cohort selection.

How do you calculate Adamax dosage for research applications?

To calculate Adamax dosage, divide the total peptide mass in milligrams by the volume of bacteriostatic water used for reconstitution to determine concentration in mg/mL, then multiply by the desired dose in micrograms and divide by 1,000 to find the injection volume in milliliters. For a 5mg vial reconstituted with 2mL bacteriostatic water, concentration equals 2.5mg/mL; a 250mcg dose requires 0.1mL injection volume.

Most guides stop at the formula and assume you'll figure out the rest. That approach fails the moment you encounter vial-to-vial potency variance, need to adjust for subject body weight in animal models, or transition between maintenance and loading doses mid-protocol. This article covers the full calculation sequence from reconstitution ratios through titration schedules, the specific concentration formulas that account for peptide purity variance, and the storage variables that alter effective dosage over a 28-day reconstituted lifespan.

Understanding Adamax Peptide Structure and Dosing Fundamentals

Adamax. Also referred to as Adipotide or FTPP (prohibitin-targeting peptide proapoptotic). Is a synthetic peptidomimetic compound designed to selectively induce apoptosis in adipose tissue vasculature by binding to prohibitin receptors on endothelial cells within white adipose tissue. The mechanism is tissue-specific: the KGGRAKD homing sequence directs the compound to blood vessels feeding fat deposits, where the proapoptotic domain triggers programmed cell death in those vessels, causing localized adipocyte loss without systemic cytotoxic effects. This isn't a metabolic accelerator or appetite suppressant. It's a targeted vascular intervention at the cellular level.

When you calculate Adamax dosage, you're working with a compound that has a molecular weight of approximately 2,611 Daltons and demonstrates dose-dependent effects that scale non-linearly. Early-phase research in rhesus macaque models published in Science Translational Medicine showed that doses below 0.5mg/kg body weight produced negligible fat mass reduction, while doses above 4mg/kg triggered adverse renal events in 30% of subjects. The therapeutic window is narrow. Dosing precision matters because the difference between a subtherapeutic dose and one that produces off-target vascular effects can be as small as 50–100mcg in smaller animal models.

Lyophilized Adamax arrives as a white to off-white powder, typically in 5mg or 10mg vials, with potency verified by HPLC at the time of synthesis. The actual peptide content will be between 92–98% of labeled mass due to the presence of excipients (usually mannitol or glycine as stabilizers) and residual moisture from the freeze-drying process. You cannot assume a 5mg vial contains exactly 5.0mg of active peptide. Real Peptides provides certificates of analysis with each batch showing the precise assay percentage, and that number must be factored into your dose calculations. A vial labeled 5mg at 94% purity contains 4.7mg of active Adamax, not 5mg.

Reconstitution requires bacteriostatic water. Never sterile saline, never plain water. Bacteriostatic Water contains 0.9% benzyl alcohol as a preservative, which prevents bacterial growth in multi-dose vials over the 28-day post-reconstitution window. The volume you add determines final concentration, and concentration determines how much liquid you draw for each dose. Most researchers default to 2mL per 5mg vial because it yields a clean 2.5mg/mL concentration, but that's a convention, not a requirement. You can use 1mL for a more concentrated solution (reducing injection volume) or 3mL for a more dilute one (increasing measurement precision if you're working with low microgram doses).

The Step-by-Step Calculation Formula to Determine Adamax Dose

The dose calculation sequence has four stages: determining peptide mass, selecting reconstitution volume, calculating concentration, and converting desired dose to injection volume. Each stage has a potential error point, so we'll walk through the complete chain with real numbers.

Stage 1: Adjust for actual peptide content

Your vial label says 5mg. The certificate of analysis shows 96.2% purity. Multiply labeled mass by purity percentage: 5mg × 0.962 = 4.81mg actual Adamax content. This is your starting mass for all subsequent calculations. Skipping this step introduces a 4–8% dosing error from the outset, which compounds across titration schedules.

Stage 2: Select bacteriostatic water volume

Standard volumes are 1mL, 2mL, or 3mL per 5mg vial. Your choice determines concentration and injection volume precision. If you're dosing in the 100–300mcg range, a 2mL reconstitution gives you injection volumes between 0.04mL and 0.12mL. Manageable with a 0.5mL insulin syringe marked in 0.01mL increments. If you're dosing above 500mcg, a 1mL reconstitution (higher concentration) keeps injection volumes below 0.2mL, reducing tissue irritation at the injection site. For ultra-low doses below 50mcg, a 3mL reconstitution increases measurement precision by spreading the dose across a larger volume.

Stage 3: Calculate concentration in mg/mL

Divide actual peptide mass by reconstitution volume. Using our 4.81mg example with 2mL bacteriostatic water: 4.81mg ÷ 2mL = 2.405mg/mL. Convert to micrograms for easier dose calculation: 2.405mg/mL × 1,000 = 2,405mcg/mL. Every milliliter of your reconstituted solution contains 2,405 micrograms of Adamax.

Stage 4: Convert desired dose to injection volume

Your protocol calls for 250mcg per administration. Divide dose by concentration: 250mcg ÷ 2,405mcg/mL = 0.104mL. Round to the nearest graduation on your syringe. In this case, 0.10mL on a 0.5mL insulin syringe. The rounding introduces a 4% variance (you're administering 240mcg instead of 250mcg), which is acceptable in most research contexts but must be documented in your methods section for reproducibility.

If your protocol specifies dose in mg/kg body weight. Common in animal models. You need one additional step. A 250g rat at 1mg/kg requires 0.25mg total dose. Convert to micrograms: 0.25mg × 1,000 = 250mcg. Then proceed to Stage 4 as above. For larger animal models, a 15kg rhesus macaque at 1mg/kg requires 15mg. Far exceeding what a single 5mg vial provides. You'd reconstitute multiple vials using the same water volume per vial to maintain concentration consistency, then draw from multiple vials or pool the reconstituted solution into a sterile container (which reduces per-vial shelf life to 7 days due to increased contamination risk).

We've reviewed dose calculation errors across hundreds of research submissions. The most common mistake isn't formula misapplication. It's unit confusion. Researchers calculate correctly in milligrams, then draw the volume in milliliters without converting, administering a dose 1,000 times higher than intended. The fix is simple: always write your final answer with units, then verify the units match your syringe graduations before drawing.

Titration Protocols and Dose Escalation Schedules for Adamax Research

Adamax is not typically administered at therapeutic dose from day one in research protocols. The standard approach uses a dose escalation schedule that allows researchers to monitor for adverse events and assess dose-response relationships before committing to higher exposures. Published primate studies used a titration model that started at 0.25mg/kg every other day for one week, increased to 0.5mg/kg for week two, then escalated to 1.0mg/kg for weeks three through eight. This stepwise approach reduces the incidence of acute renal effects, which appeared in 12% of subjects who started at 1mg/kg without titration versus 3% in the escalation group.

For rodent models, typical starting doses range from 0.5mg/kg to 1mg/kg administered subcutaneously every 48 hours. A 250g rat at 0.5mg/kg receives 125mcg per dose. Using the 2,405mcg/mL concentration from our earlier example, that's 0.052mL injection volume. After one week with no adverse clinical signs (measured by body weight, food intake, and serum creatinine levels), the dose increases to 1mg/kg. 250mcg per dose, or 0.104mL. The escalation continues weekly in 0.5mg/kg increments until either the target dose is reached or adverse events appear.

Dose frequency matters as much as dose magnitude. Adamax has an estimated half-life of 6–8 hours in rodent models based on plasma clearance studies, meaning daily dosing maintains more stable plasma levels than every-other-day dosing, but also increases cumulative exposure and the risk of off-target vascular effects. Most published protocols use every-other-day (EOD) administration as a compromise between efficacy and safety. If your research question requires daily dosing, reduce the per-dose amount by 30–40% to keep weekly cumulative exposure equivalent to an EOD protocol at higher individual doses.

Maintenance dosing comes into play once target fat mass reduction is achieved. In the rhesus macaque study, subjects who reached 20% body fat reduction were transitioned from 1mg/kg EOD to 0.5mg/kg twice weekly to prevent rebound adipocyte proliferation without sustaining the apoptotic pressure that caused renal stress at higher cumulative exposures. The maintenance phase calculation is identical to the loading phase. You're just plugging in a different target dose. The reconstituted vial concentration doesn't change, so your injection volume simply scales with the new dose.

One critical titration consideration: if you're comparing Adamax to other research peptides in a crossover or combination design, the washout period must account for downstream vascular remodeling, not just peptide clearance. Even though Adamax clears plasma within 24–48 hours, the apoptotic cascade it triggers in adipose vasculature continues for 7–10 days post-administration. Starting a new intervention before that cascade resolves introduces confounding variables. Standard washout between Adamax cessation and the next peptide exposure is 14 days minimum.

Calculate Adamax Dosage: Research Model Comparison

The table below compares dosing parameters across common research models using a standardized 5mg vial reconstituted with 2mL bacteriostatic water (2.5mg/mL concentration, adjusted for 96% purity = 2,405mcg/mL).

| Research Model | Body Weight | Dose (mg/kg) | Total Dose (mcg) | Injection Volume (mL) | Frequency | Professional Assessment |
|—|—|—|—|—|—|
| Mouse (C57BL/6) | 25g | 1.5 mg/kg | 37.5 mcg | 0.016 mL | Every 48 hours | Requires diluted reconstitution (3mL per vial) for accurate measurement; volumes below 0.02mL prone to air bubble error |
| Rat (Sprague-Dawley) | 250g | 1.0 mg/kg | 250 mcg | 0.104 mL | Every 48 hours | Standard model for Adamax adipose research; dose volume manageable with insulin syringes; monitor serum creatinine weekly |
| Rabbit (New Zealand White) | 3.5 kg | 0.75 mg/kg | 2,625 mcg | 1.09 mL | Every 72 hours | Multi-vial pooling required; reduced frequency limits cumulative renal exposure; subcutaneous administration in dorsal region |
| Rhesus Macaque | 8 kg | 1.0 mg/kg | 8,000 mcg | 3.33 mL | Every 48 hours (weeks 3–8) | Requires pooling from 2 vials; closest translational model to human dosing; GFR monitoring mandatory at doses above 0.5mg/kg |
| In Vitro (adipocyte culture) | N/A | N/A | 10–100 nM final concentration | Varies by well volume | Single exposure or 24h repeat | Requires molecular weight conversion (2,611 Da); 100nM in 2mL media = 0.52mcg total; use serial dilution from stock |

This comparison assumes subcutaneous administration for in vivo models. Intravenous dosing increases bioavailability to near 100% (versus 60–70% for subcutaneous), requiring dose reduction by 30–40% to achieve equivalent systemic exposure. Intraperitoneal administration in rodents shows intermediate bioavailability around 75–80% and is sometimes preferred for reducing injection site reactions in chronic dosing protocols, though it introduces more variability in absorption kinetics than subcutaneous.

What If: Adamax Dosage Scenarios

What If the Reconstituted Solution Looks Cloudy or Contains Particles?

Discard the vial immediately and do not administer. Cloudiness or visible particles indicate either contamination introduced during reconstitution, aggregation of the peptide due to improper storage temperature, or a manufacturing defect. Adamax in solution should be clear to slightly opalescent with no visible particulate matter. Filtering through a 0.22-micron syringe filter will not rescue a contaminated or aggregated solution. The peptide structure has already been compromised. Document the lot number and contact the supplier for a replacement; Real Peptides maintains full traceability on every batch and will investigate any reported solution clarity issues.

What If I Need to Dose Below 50 Micrograms in a Mouse Model?

Increase your reconstitution volume to 3mL or 4mL per 5mg vial, which dilutes the concentration and spreads low-microgram doses across a larger, more measurable injection volume. A 30g mouse at 1mg/kg requires 30mcg. With standard 2mL reconstitution (2,405mcg/mL), that's 0.0125mL. Below the reliable measurement threshold for most insulin syringes. Reconstituting with 4mL instead yields 1,202mcg/mL concentration, making the same 30mcg dose equal 0.025mL, which is easier to measure accurately and less prone to air bubble error that disproportionately affects ultra-low volumes.

What If My Protocol Requires Dosing by Surface Area Instead of Body Weight?

Convert body surface area (BSA) to an equivalent mg/kg dose using the species-specific BSA formula, then proceed with standard dose calculation. For rats, BSA in square meters equals 0.09 × (body weight in grams)^0.67 ÷ 10,000. A 250g rat has a BSA of approximately 0.025 m². If your protocol specifies 40mg/m² Adamax, multiply by BSA: 40mg/m² × 0.025m² = 1mg total dose. The calculation bypasses mg/kg entirely and goes straight to total dose in milligrams, which you then convert to injection volume using your reconstituted concentration.

What If I Accidentally Left Reconstituted Adamax at Room Temperature Overnight?

Do not use it. Temperature excursions above 8°C denature the peptide's prohibitin-binding domain, rendering it biologically inactive without altering its appearance. There is no at-home potency test that can confirm whether the structure is intact. GLP-1 receptor agonists like Tirzepatide and Semaglutide tolerate brief temperature deviations, but Adamax's peptidomimetic structure is less thermostable. A single overnight exposure at 20–25°C can reduce binding affinity by 40–60%, invalidating your dose-response data. Discard the vial, document the incident in your protocol deviation log, and reconstitute a fresh vial.

What If the Certificate of Analysis Shows Purity Below 90%?

Contact the supplier before using the peptide. Purity below 90% suggests either degradation during storage or an issue with the synthesis batch. Reputable peptide suppliers like Real Peptides guarantee minimum 95% purity by HPLC for research-grade compounds; anything below that threshold should trigger a replacement or refund. If you proceed with a low-purity vial, you must adjust your dose calculation by the actual purity percentage, but more importantly, the impurities present (truncated sequences, deletion analogs, or synthesis byproducts) may introduce off-target effects that confound your results.

The Unforgiving Truth About Adamax Dosage Precision

Here's the honest answer: most peptide research fails not because of bad science, but because of arithmetic errors compounded by overconfidence in visual inspection. You cannot tell by looking at a vial whether your concentration is correct. You cannot tell by looking whether the peptide degraded during storage. You cannot tell whether your syringe drew 0.10mL or 0.12mL unless you're using calibrated measurement under proper lighting with a steady hand.

The difference between a publishable result and a failed protocol often comes down to whether you treated dose calculation as a step to rush through or as the foundation of the entire study. We've seen researchers skip the purity adjustment because